Crocin improves renal function by declining Nox-4, IL-18, and p53 expression levels in an experimental model of diabetic nephropathy

Journal of Cellular Biochemistry

Volumn 119, Issue 7, 2018, Pages 6080-6093

  Yaribeygi, Habib ^a,b   Mohammadi, Mohammad T ^a   Rezaee, Ramin ^c   Sahebkar, Amirhossein ^c,d  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

antioxidant defense system; crocin; diabetic nephropathy; hyperglycemia; IL 18; NOX 4

Indexed keywords

CATALASE; CREATININE; CROCIN; FREE RADICAL; GLUCOSE; GLUTATHIONE; INTERLEUKIN 18; MALONALDEHYDE; MESSENGER RNA; NITRATE; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; STREPTOZOCIN; SUPEROXIDE DISMUTASE; UREA; URIC ACID; CAROTENOID; NOX4 PROTEIN, MOUSE; TRP53 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; KIDNEY FUNCTION; KIDNEY TISSUE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINE SAMPLING; ANIMAL; COMPLICATION; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY FUNCTION TEST; METABOLISM; WISTAR RAT;

ANIMALS; CAROTENOIDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; INTERLEUKIN-18; KIDNEY FUNCTION TESTS; MALE; NADPH OXIDASE 4; RATS; RATS, WISTAR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85044399259     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.26806     Document Type: Article

References (55)

1. Herman WH, Zimmet P. Type 2 diabetes: an epidemic requiring global attention and urgent action. Diabetes Care. 2012; 35:943–944.
2. Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes. 2012; 19:93–96.
3. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010; 8:29.
4. Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy. Prog Modern Biomed. 2014; 16:050.
5. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002; 346:1145–1151.
6. Yamagishi S-i, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longevity. 2010; 3:101–108.
7. Navarro-González JF, Mora-Fernández C, de Fuentes MM, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011; 7:327–340.
8. Ndisang JF, Jadhav A. Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis. Endocrinology. 2013; 155:215–229.
9. Kanwar YS, Sun L, Xie P, Liu F-y, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011; 6:395–423.
10. Fujita T, Ogihara N, Kamura Y, et al. Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol. 2012; 49:111–117.
11. Tavafi M. Diabetic nephropathy and antioxidants. J Nephropathol. 2013; 2:20.
12. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci. 2013; 124:139–152.
13. Miyauchi K, Takiyama Y, Honjyo J, Tateno M, Haneda M. Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: tGF-β 1 enhanced IL-18 expression in human renal proximal tubular epithelial cells. Diabetes Res Clin Pract. 2009; 83:190–199.
14. Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K. Interleukin-18 enhances monocyte tumor necrosis factor α and interleukin-1β production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum. 2004; 50:432–443.
15. Okamura H, Tsutsui H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature. 1995; 378:88–91.
16. Reddy P. Interleukin-18: recent advances. Curr Opin Hematol. 2004; 11:405–410.
17. Suchanek H, Myśliwska J, Siebert J, et al. High serum interleukin-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus. Eur Cytokine Netw. 2005; 16:177–185.
18. Yaribeygi H, Farrokhi FR, Rezaee R, Sahebkar A. Oxidative stress induces renal failure: a review of possible molecular pathways. J Cell Biochem. 2018; 119:2990–2998.
19. Stadler K. Oxidative stress in diabeteseditor^editors. Diabetes. Springer, p 2013;272–287.
20. Fujii M, Inoguchi T, Maeda Y, et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int. 2007; 72:473–480.
21. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway. Diabetes. 2008; 57:460–469.
22. Sedeek M, Callera G, Montezano A, et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2010; 299:F1348.
23. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal. 2006; 8:1597–1607.
24. Kashihara N, Haruna Y, Kondeti V, Kanwar Y. Oxidative stress in diabetic nephropathy. Curr Med Chem. 2010; 17:4256.
25. Kumar D, Robertson S, Burns KD. Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem. 2004; 259:67–70.
26. Susztak K, Raff AC, Schiffer M, Böttinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006; 55:225–233.
27. Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res. 2008; 42:397–404.
28. Aung H, Wang C, Ni M, et al. Crocin from Crocus sativus possesses significant anti-proliferation effects on human colorectal cancer cells. Exp Oncol. 2007; 29:175.
29. Ochiai T, Ohno S, Soeda S, Tanaka H, Shoyama Y, Shimeno H. Crocin prevents the death of rat pheochromyctoma (PC-12) cells by its antioxidant effects stronger than those of α-tocopherol. Neurosci Lett. 2004; 362:61–64.
30. El-Beshbishy HA, Hassan MH, Aly HA, Doghish AS, Alghaithy AA. Crocin “saffron” protects against beryllium chloride toxicity in rats through diminution of oxidative stress and enhancing gene expression of antioxidant enzymes. Ecotoxicol Environ Saf. 2012; 83:47–54.
31. Li K, Li Y, Ma Z, Zhao J. Crocin exerts anti-inflammatory and anti-catabolic effects on rat intervertebral discs by suppressing the activation of JNK. Int J Mol Med. 2015; 36:1291–1299.
32. Poma A, Fontecchio G, Carlucci G, Chichiricco G. Anti-inflammatory properties of drugs from saffron crocus. Antiinflamm Antiallergy Agents Med Chem. 2012; 11:37–51.
33. Altinoz E, Oner Z, Elbe H, Cigremis Y, Turkoz Y. Protective effects of saffron (its active constituent, crocin) on nephropathy in streptozotocin-induced diabetic rats. Hum Exp Toxicol. 2015; 34:127–134.
34. Winterbourn CC, Hawkins RE, Brian M, Carrell R. The estimation of red cell superoxide dismutase activity. Transl Res. 1975; 85:337–341.
35. Aebi H. [13] catalase in vitro. Methods Enzymol. 1984; 105:121–126.
36. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969; 27:502–522.
37. Satoh M, Fujimoto S, Haruna Y, et al. NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2005; 288:F1144.
38. Granger DL, Taintor RR, Boockvar KS, Hibbs JB. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol. 1996; 268:142–151.
39. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107:1058–1070.
40. Yaribeygi H, Mohammadi M. 2017. Protective effect of crocin on kidney performance in chronic uncontrolled hyperglycemia-induced nephropathy in rat.
41. Thallas-Bonke V, Jha JC, Gray SP, et al. Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy. Physiol Rep. 2014; 2:e22192.
42. Sachdeva J, Tanwar V, Golechha M, et al. Crocus sativus L.(saffron) attenuates isoproterenol-induced myocardial injury via preserving cardiac functions and strengthening antioxidant defense system. Exp Toxicol Pathol. 2012; 64:557–564.
43. Hosseinzadeh H, Sadeghnia HR. Safranal, a constituent of Crocus sativus (saffron), attenuated cerebral ischemia induced oxidative damage in rat hippocampus. J Pharm Pharm Sci. 2005; 8:394–399.
44. Nakamura A, Shikata K, Hiramatsu M, et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 2005; 28:2890–2895.
45. Nam KN, Park Y-M, Jung H-J, et al. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol. 2010; 648:110–116.
46. Hemshekhar M, Santhosh MS, Sunitha K, et al. A dietary colorant crocin mitigates arthritis and associated secondary complications by modulating cartilage deteriorating enzymes, inflammatory mediators and antioxidant status. Biochimie. 2012; 94:2723–2733.
47. El-Maraghy SA, Rizk SM, Shahin NN. Gastroprotective effect of crocin in ethanol-induced gastric injury in rats. Chem Biol Interact. 2015; 229:26–35.
48. Deshpande SD, Putta S, Wang M, et al. Transforming growth factor-β-Induced cross talk between p53 and a MicroRNA in the pathogenesis of diabetic nephropathy. Diabetes. 2013; 62:3151–3162.
49. Fiordaliso F, Leri A, Cesselli D, et al. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes. 2001; 50:2363–2375.
50. Eid AA, Ford BM, Block K, et al. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol Chem. 2010; 285:37503–37512.
51. Kodama T, Takehara T, Hikita H, et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest. 2011; 121:3343–3356.
52. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010; 31:37–49.
53. Amin A, Bajbouj K, Koch A, Gandesiri M, Schneider-Stock R. Defective autophagosome formation in p53-null colorectal cancer reinforces crocin-induced apoptosis. Int J Mol Sci. 2015; 16:1544–1561.
54. Sun Y, Yang J, Wang L, Sun L, Dong Q. Crocin attenuates cisplatin-induced liver injury in the mice. Hum Exp Toxicol. 2014; 33:855–862.
55. Bahem R, Hoffmann A, Azonpi A, Caballero-George C, Vanderheyden P. Modulation of calcium signaling of angiotensin AT1, endothelin ETA, and ETB receptors by silibinin, quercetin, crocin, diallyl sulfides, and ginsenoside Rb1. Planta Med. 2015; 81:670–678.